Literature DB >> 33641875

Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications.

Ruben Mesa1, Jeanne Palmer2, Ryan Eckert3, Jennifer Huberty3.   

Abstract

Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Integrative medicine; Myeloproliferative neoplasm; Quality of life

Mesh:

Year:  2021        PMID: 33641875     DOI: 10.1016/j.hoc.2020.12.006

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  1 in total

Review 1.  Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.

Authors:  Ivan Krecak; Marko Lucijanic; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.